Paul Hastings Advises TD Cowen, Leerink Partners and Oppenheimer & Co. in Ovid Therapeutics’ PIPE Financing
Paul Hastings advised TD Cowen, Leerink Partners and Oppenheimer & Co. as placement agents in Ovid Therapeutics Inc.’s (Nasdaq: OVID) private investment in public equity financing. The financing is expected to result in gross proceeds of up to $175 million, including initial gross proceeds of approximately $81 million, and close on or about Oct. 6, 2025, subject to customary closing conditions.
Equity Capital Markets and Corporate Life Sciences chair Seo Salimi and partner Will Magioncalda led the Paul Hastings team, which included associate Chris Guerin.
More details can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.